Cell Differentiation Control Through Forced MYC–BMI1 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for inducing cell differentiation from hematopoietic progenitor cells and human ES/iPS cells face limitations such as limited proliferation, non-uniform cell quality, complex differentiation processes, and low efficiency, making it difficult to produce sufficient cells for drug screening and cell therapy applications.
Innovation Solution
Regulating cell differentiation by forcibly expressing the MYC family gene and the BMI1 gene in mesenchymal stromal cells, vascular endothelial cells, smooth muscle cells, neural crest cells, lymphocytes, megakaryocytes, and myelocytes, allowing for the production of progenitor and differentiated cells with controlled differentiation states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods using hematopoietic progenitor cells from umbilical cord blood or bone marrow are used, then neutrophils and macrophages can be obtained by adding growth factors, but proliferation of the source cells is limited and it is difficult to prepare a large amount of cells with uniform quality
Solution Approach 1:
The patent changes the genetic parameters of the source cells by introducing and overexpressing specific genes (c-Myc, Bcl-xL, and/or Telomerase reverse transcriptase) to transform the proliferation characteristics of hematopoietic progenitor cells, enabling them to proliferate extensively in vitro while maintaining differentiation potential
Solution Approach 2:
The patent creates immortalized cell lines that can be repeatedly cultured and passaged, effectively copying the progenitor cell population indefinitely. These immortalized cells serve as a renewable source that can be expanded to large quantities without exhausting the original limited proliferative capacity
2Productivity
If conventional methods using human ES/iPS cells are used, then cells can proliferate indefinitely, but the differentiation process is complicated and efficiency is low
Solution Approach 1:
The patent extracts and overexpresses specific key regulatory genes (c-Myc, Bcl-xL, and/or Telomerase reverse transcriptase) that control proliferation and differentiation, separating these critical functions from the complex natural differentiation process. This allows simplified control over cell fate decisions
Solution Approach 2:
The patent modifies the genetic expression parameters of the cells by introducing exogenous genes or overexpressing endogenous genes, which fundamentally changes the differentiation trajectory and efficiency, enabling high-yield production of specific cell types from pluripotent stem cells
3Productivity
If immortalized cell lines from leukemia patients are used, then cell lines can be established, but they express leukemia mutated genes constitutively and normal differentiation is not possible
Solution Approach 1:
The patent converts the typically harmful immortalization process (which usually requires oncogenic mutations) into a beneficial controlled process by using specific gene combinations (c-Myc with Bcl-xL and/or Telomerase) that provide immortalization without the detrimental effects of leukemia-associated mutations, preserving normal differentiation capability
Solution Approach 2:
The patent precisely controls the genetic parameters by introducing specific genes in controlled combinations and expression levels, creating immortalized cells with normal differentiation potential rather than the uncontrolled, mutated state found in leukemia-derived cell lines
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a method for regulating the degree of cell differentiation including a step of forcibly expressing the MYC family gene and the BMI1 gene in cells selected from the group consisting of (i) mesenchymal stromal cells, vascular endothelial cells, smooth muscle cells, neural crest cells, and lymphocytes having any degree of differentiation, and (ii) megakaryocytes and myelocytes having a high degree of differentiation.